CDC IXIS Innovation

Summary

The company was established in Europe in France. The main office of represented VC is situated in the Paris.

For fund there is a match between the location of its establishment and the land of its numerous investments - France. Among the most popular portfolio startups of the fund, we may highlight Kuros Biosciences, OneAccess, NEMOPTIC. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Biopharma, Mobile.

Deals in the range of 5 - 10 millions dollars are the general things for fund. Opposing the other organizations, this CDC IXIS Innovation works on 21 percentage points more the average amount of lead investments. Considering the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The increased amount of exits for fund were in 2017. The fund is generally included in less than 2 deals every year. The important activity for fund was in 2002.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the CDC IXIS Innovation, startups are often financed by Viventures Partners SA, Ventech, Eurazeo. The meaningful sponsors for the fund in investment in the same round are Auriga Partners, Viventures Partners SA, Venture Incubator, LLC. In the next rounds fund is usually obtained by Ventech, VI Partners AG, VINCI CAPITAL.